FDA approves new kind of treatment for hairy cell leukemia

September 13, 2018 – The U.S. Food and Drug Administration today approved moxetumomab pasudotox-tdfk injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Moxetumomab pasudotox-tdfk is a CD22-directed cytotoxin and is the first of this type of treatment for patients with HCL. “Moxetumomab … (leggi tutto)